JG
AKBA icon

Joel Greenblatt’s Akebia Therapeutics AKBA Stock Holding History

Joel Greenblatt’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.1K Buy
36,053
+8,881
+33% +$10.6K ﹤0.01% 1784
2026
Q1 		$37.8K Buy
27,172
+11,202
+70% +$15.4K ﹤0.01% 1742
2025
Q4 		$25.7K Buy
15,970
+1,471
+10% +$3.08K ﹤0.01% 1718
2025
Q3 		$39.6K Sell
14,499
-1,070
-7% -$3.56K ﹤0.01% 1669
2025
Q2 		$56.7K Buy
+15,569
New +$42.8K ﹤0.01% 1640
2021
Q3 		– Sell
-19,195
Closed -$73K – 1013
2021
Q2 		$73K Buy
+19,195
New +$64.6K ﹤0.01% 979

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Joel Greenblatt's AKBA Position: Q2 2026 in Review

Joel Greenblatt increased its Akebia Therapeutics (AKBA) stake by 33% in Q2 2026, buying an estimated $10.6K and bringing the position to 36,053 shares worth $41.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1784.

Joel Greenblatt first reported a position in AKBA in Q2 2021 and has held it in 6 quarters since. The position peaked at $73K in Q2 2021. 169 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Joel Greenblatt held 36,053 shares of Akebia Therapeutics worth $41.1K as of Q2 2026.
  • Joel Greenblatt bought 8,881 Akebia Therapeutics shares in Q2 2026, an estimated $10.6K.
  • Akebia Therapeutics made up ﹤0.01% of Joel Greenblatt's portfolio in Q2 2026, its #1784 holding.
  • Joel Greenblatt first reported a position in Akebia Therapeutics in Q2 2021 and has held it in 6 quarters since.
  • Joel Greenblatt's Akebia Therapeutics position peaked at $73K in Q2 2021.
  • 169 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.